PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Inclusion Criteria

• •1. Histologically confirmed Richter's transformation (RT) from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
• •2. Availability of fresh or archived tumor tissue.
• •3. FDG PET-CT (disease) positive baseline scan with measurable disease.
• •4. ECOG performance status of 0-1.
• •5. Evidence of disease progression at study entry.
• •6. Discontinuation of prior anticancer therapy for ≥ 7 days prior to C1D1 and recovered to ≤ CTCAE grade 2 (or baseline) from any acute or chronic toxicity associated with prior therapy.
• •7. Must have previously received at least one prior chemotherapeutic regimen for RT.
• •\- Previously untreated RT patients deemed ineligible for, or that refuse, intensive chemotherapy are eligible.
• •8. Adequate bone marrow, renal, and hepatic function.
• •9. Normal Coagulation profile.
• •10. Agreement to use acceptable methods of contraception during the study and for ≥ 120 days after the last dose of PNT2258 if sexually active and able to bear or beget children.
• •11. Ability to participate in the clinical study for a minimum of at least 2 cycles (6 weeks).